Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man

Cardiovascular Research

Volumn 36, Issue 2, 1997, Pages 268-275

  Newby, David E ^a   Masumori, Satoko ^b   Johnston, Neil R ^a   Boon, Nicholas A ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Arteries; Blood flow; Human; Losartan; Sodium depletion

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BRADYKININ; LOSARTAN; NORADRENALIN;

ADRENERGIC STIMULATION; ADULT; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM DEFICIENCY; SODIUM DEPLETION; VASOCONSTRICTION;

ADULT; ANALYSIS OF VARIANCE; ANGIOTENSIN I; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BLOOD VESSELS; BRADYKININ; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOREARM; FUROSEMIDE; HUMANS; LOSARTAN; LOWER BODY NEGATIVE PRESSURE; MALE; NOREPINEPHRINE; RECEPTORS, ANGIOTENSIN; REGIONAL BLOOD FLOW; SODIUM; SODIUM, DIETARY; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0031281698     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00171-5     Document Type: Article

References (36)

1. Johnston C.I. Angiotensin receptor antagonists: focus on losartan. Lancet. 346:1995;1403-1407.
2. Brough R.B., Cowley A.W., Guyton A.C. Quantitative analysis of the acute response to hemorrhage of the renin-angiotensin-vasoconstrictor feedback loop in areflexic dogs. Cardiovasc Res. 9:1975;722-733.
3. Collier J.G., Robinson B.F., Vane J.R. Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (SQ 20,881) which inhibits converting enzyme. Lancet. i:1973;72-74.
4. Seidelin P.H., Collier J.G., Struthers A.D., Webb D.J. Angiotensin II augments sympathetically mediated arteriolar constriction in man. Clin Sci. 81:1991;261-266.
5. Hjemdahl P., Friberg P. Biochemical assessment of sympathetic activity and prejunctional modulation of noradrenaline release in humans. J Hypertens. 14:1996;147-150.
6. Goldberg M.R., Tanaka W., Barchowsky A.et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension. 21:1993;704-713.
7. Ohtawa M., Takayama F., Saitoh K., Yoshinaga T., Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol. 35:1993;290-297.
8. Doig J.K., MacFadyen R.J., Sweet C.S., Reid J.L. Hemodynamic and renal responses to oral losartan potassium during salt depletion or salt repletion in normal human volunteers. J Cardiovasc Pharmacol. 25:1995;511-517.
9. Webb D.J. The pharmacology of human blood vessels in vivo. J Vasc Res. 32:1995;2-15.
10. Benjamin N., Calver A., Collier J., Robinson B., Vallance P., Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension. 25:1995;918-923.
11. Vallance P., Collier J., Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. ii:1989;997-1000.
12. Haynes W.G., Webb D.J. Contribution of endogenous generation of endothelin-1 to basal vascular tone in man. Lancet. 344:1994;852-854.
13. Haynes W.G., Noon J.P., Walker B.R., Webb D.J. L-NMMA increases blood pressure in man. Lancet. 342:1993;931-932.
14. Haynes W.G., Ferro C.J., O'Kane K.P.J., Sommerville D., Lomax C.C., Webb D.J. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in man. Circulation. 93:1996;1860-1870.
15. Webb DJ. Sympathetic vasoconstriction and local converting enzyme activity within the upper limb circulation in man: studies with particular relevance to the action of angiotensin. MD Thesis, University of London, 1990.
16. Taddei S., Virdis A., Mattei P., Favilla S., Salvetti A. Angiotensin II and sympathetic activity in sodium-restricted essential hypertension. Hypertension. 25:1995;595-601.
17. Wiinberg N., Walter-Larson S., Eriksen C., Nielsen P.E. An evaluation of semi-automatic blood pressure manometers against intra-arterial blood pressure. J Ambulatory Monitoring. 1:1988;303-309.
18. Webb D.J., Manhem P.J.O., Ball S.G.et al. A study of the renin inhibitor H142 in man. J Hypertens. 3:1985;653-658.
19. Plumpton C., Haynes W.G., Webb D.J., Davenport A.P. Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. Br J Pharmacol. 116:1995;1821-1828.
20. Morton J.J., Webb D.J. Measurement of plasma angiotensin II. Clin Sci. 68:1985;483-484.
21. Rolinski B., Bogner S.J., Goebel F.D. Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med. 194:1994;9-24.
22. Haber E., Koerner T., Page L.B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 29:1969;1349-1355.
23. Benjamin N., Cockcroft J.R., Collier J.G., Dollery C.T., Ritter J.M., Webb D.J. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 412:1989;543-555.
24. Clarke J.G., Benjamin N., Larkin S.W., Webb D.J., Davies G.J., Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol. 257:1989;H2033-H2035.
25. Cockcroft J.R., Sciberras D.G., Goldberg M.R., Ritter J.M. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol. 22:1993;579-584.
26. Baan J., Chang P.C., Vermeij P., Pfaffendorf M., van Zwieten P.A. Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed. Cardiovasc Res. 32:1996;973-979.
27. MacGregor G.A. Dietary sodium and blood pressure. Lancet. 343:1994;545-546.
28. Jacobs M.C., Goldstein D.S., Willemsen J.J., Smits P., Thien T., Lenders J.W.M. Differential effects of low- and high-intensity lower body negative pressure on noradrenaline and adrenaline kinetics in humans. Clin Sci. 90:1996;337-343.
29. Clemson B., Gaul L., Gubin S.S.et al. Prejunctional angiotensin II receptors. J Clin Invest. 93:1994;684-691.
30. Goldsmith S.R., Rector T.S., Bank A.J., Garr M., Kubo S.H. Effect of angiotensin II on noradrenaline release in the human forearm. Cardiovasc Res. 26:1994;663-666.
31. Duranteau J., Pussard E., Berdeaux A., Giudicelli J.F. Effects of the angiotensin type I receptor antagonist, losartan, on systemic and regional vascular responses to lower body negative pressure in healthy volunteers. Br J Clin Pharmacol. 40:1995;431-438.
32. Wong P.C., Price W.A., Chiu A.T.et al. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 255:1990;211-217.
33. De Gasparo M., Levens N.R. Pharmacology of angiotensin II receptors in the kidney. Kidney Int. 46:1994;1486-1491.
34. Aguirre J.A., Fuxe K., Hedlund P.et al. Neuropeptide Y/angiotensin II interactions in central cardiovascular regulation of the rat. Brain Res. 566:1991;61-69.
35. MacGregor D.P., Murone C., Song K., Allen A.M., Paxinos G., Mendelsohn F.A.O. Angiotensin II receptor subtypes in the human central nervous system. Brain Res. 675:1995;231-240.
36. Crozier I., Ikram H., Awan N.et al. Losartan in heart failure: hemodynamic effects and tolerability. Circulation. 91:1995;691-697.